CoChat

Cancerous inhibitor of PP2A is targeted by natural compound celastrol for degradation in non-small-cell lung cancer

Open access
Liu, Zi, Ma, Liang, Wen, Zhe-Sheng, Hu, Zheng, Wu, Fu-Qun, Li, Wei, Liu, Jinsong, Zhou, Guang-Biao · 2014 · Carcinogenesis
Cited by 105

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Celastrol binds CIP2A and enhances CIP2A–CHIP interaction, leading to ubiquitination/degradation of CIP2A and inhibition of lung cancer cells in vitro and in vivo. Celastrol potentiates cisplatin’s efficacy by suppressing the CIP2A–Akt pathway, and therefore CIP2A inhibitors may represent novel therapeutics for cancer. Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein overexpressed and inversely associated with prognosis in lung and many other human cancers. It modulates phospho-Akt and stabilizes c-Myc, and is required for cell proliferation and malignant transformation, indicating that CIP2A may play an important role in carcinogenesis. We reported here that a small compound celastrol could induce a rapid degradation of CIP2A, through the ubiquitin–proteasome pathway with the carboxyl terminus of Hsp70-interacting protein (CHIP) as the E3 ligase. Celastrol directly bound CIP2A protein and promoted CIP2A–CHIP interaction, leading to subsequent degradation of CIP2A in non-small-cell lung cancer cells. Furthermore, celastrol effectively inhibited cell proliferation and induced apoptosis in non-small-cell lung cancer cells, whereas CIP2A silencing enhanced these effects. Celastrol also suppressed tumor growth in xenograft murine models. In addition, celastrol potentiated the inhibitory effect of cytotoxic agent cisplatin on lung cancer cells in vitro and in vivo via inhibition of CIP2A–Akt pathway. These data indicate that celastrol is a CIP2A-targeting agent that may have therapeutic potentials in lung cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/carcin/bgt395

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 105

Metadata

Authors
Liu, Z., Ma, L., Wen, Z.-S., Hu, Z., Wu, F.-Q., Li, W., Liu, J., & Zhou, G.-B.
Venue
Carcinogenesis
Published
2013-11-30
Volume
35
Issue
4
Pages
905-914
ISSN
  • 0143-3334 (ISSN-L)
  • 1460-2180
OpenAlex
W2143939751
Cited by
105
References
11
FWCI
18.21
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cancerous inhibitor of PP2A is targeted by natural compound celastrol for degradation in non-small-cell lung cancer. https://app.cochat.ai/papers/10.1093/carcin/bgt395
The paper
Liu, Z., Ma, L., Wen, Z.-S., Hu, Z., Wu, F.-Q., Li, W., Liu, J., & Zhou, G.-B. (2014). Cancerous inhibitor of PP2A is targeted by natural compound celastrol for degradation in non-small-cell lung cancer. Carcinogenesis. https://doi.org/10.1093/carcin/bgt395

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.